The Latest Breaking News from Rinvoq

AbbVie Stock: Analyst Estimates & Ratings

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

Barchart · Jan 30

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

Barchart · Dec 24, 2025

Should You Buy This Blue-Chip Dividend Stock at Record Highs?

AbbVie shares have hit record highs after extending Rinvoq’s patent protection to 2037, boosting confidence in future earnings and dividend growth, with analysts seeing steady fundamentals and modest upside as the company’s immunology pipeline drives results.

Barchart · Sep 17, 2025

3 Defensive Dividend Stocks to Scoop Up Now

Amid ongoing market uncertainty, Morgan Stanley believes these three defensive dividend-paying stocks could be ideal buys now.

Barchart · Aug 20, 2024

AbbVie’s Call Action Suggests It Might Just Be a Buy

Barchart.com’s Unusual Options Activity on Wednesday had 18 AbbVie call options in the Top 100. Not everyone believes it’s an excellent time to buy ABBV stock. Yesterday’s options market says otherwise.

Barchart · Apr 13, 2023